News & Events – Sumitovant

Select Company

August 05, 2020Altavant Sciences Presentation at ATS 2020 Confirms Minimal Brain Exposure of Peripherally Acting Serotonin Modulator, Rodatristat Ethyl, in Clinical Development for PAH
May 02, 2020Altavant Sciences Appoints Respiratory Disease Medical Expert as Chief Medical Officer
March 02, 2020Altavant Sciences Appoints Respiratory Disease Medical Expert as Chief Medical Officer
January 08, 2020Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
October 22, 2019Altavant Sciences Presents Data at CHEST 2019 Supporting Once-Daily Dosing of Rodatristat Ethyl for the Treatment of Pulmonary Arterial Hypertension
October 18, 2019Altavant Sciences to Present Data Supporting Once-Daily Dosing of Rodatristat Ethyl at CHEST 2019
October 01, 2019Altavant Sciences Presents Data at ERS International Congress 2019 Demonstrating Strong Safety and Tolerability Profile of Rodatristat Ethyl
September 24, 2019Altavant Sciences to Present New Rodatristat Ethyl Clinical Biomarker and Safety Findings at the ERS International Congress 2019
September 05, 2019Altavant Sciences Presents Patient-Centric Approach to Drug Development at PHA’s Annual PHPN Symposium
August 05, 2019Altavant Sciences Initiates Phase 2a Study of Rodatristat Ethyl in Pulmonary Arterial Hypertension
1 2 Next »